Skip to main content

Table 2 Median dose of temozolamide, in vivo immunologial and clinical response, duration of response and median overall survival

From: Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients

Patient ID Median dose/cycle of induction temozolamide (mg) first 4 cycles No. vaccinations Median no. of cells administered 106(range) DTH Best response after 4 or more vaccinations L/H KLH Vitiligo Clinical response Response duration (months) OS (months) After vaccination treatments
28 1400 12 12.6 +++ +++ - SD 9 12 None
(11.5–17)
29 1400 first 2 cycles, 700 last 2 cycles 4 7.7 PD   3 None
(5.4–8.6)
30 1400 5 11,9 PD   6 None
(11.5–14)
31 1400 8 12.6 SD 4 7 None
(11.1–15.3)
32 1400 first 3 cycles, 700 last cycle 5 8.5 PD   6 None
(7.5–10)
33 1400 8 8.8 +++ +++ + SD 4 12 BIOCT
(4.9–10)
34 1400 6 10.1 PD   14 None
(6.9–14.5)
35 1400 17 9.4 ++ SD 10 36+ antiCTLA4Ab
(6.5–10.8)
36 1400 6 9.8 + + SD 9 41+ antiCTLA4Ab
(8.3–13.9)
37 1400 first cycle, 700 last 3 cycles 17 7.8 ++ SD 4 16 None
(5.7–10)
38 1400 11 9.3 + PD   12 None
(8.1–10.8)
39 1400 5 10 PD   7 None
(10–10)
40 1400 5 11.3 PD   4 None
(10–15)
41 700 10 9.3 +++ PR 6 14 None
(5.8–10)
42 700 4 10 PD   4 None
(10–10)
43 700 5 10 + + PD   8 None
(9.6–13.8)
44 700 7 10 + PD   10 antiCTLA4Ab
(10–10)
  1. BIOCT Biochemotherapy, anti-CTLA4Ab antibody against CTLA4, PD Progressive disease, SD Stable disease,PR Partial response, Os Overall survival, DTH Delayed-type hypersensitivity, KLH Keyhole limpet hemocyanin, L/H Lysate/homogenate, + Patients alive in December 2011.